These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 1801534)
1. Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review. Burns RS Acta Neurol Scand Suppl; 1991; 136():29-36. PubMed ID: 1801534 [TBL] [Abstract][Full Text] [Related]
3. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
4. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409 [TBL] [Abstract][Full Text] [Related]
5. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Pifl C; Schingnitz G; Hornykiewicz O Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053 [TBL] [Abstract][Full Text] [Related]
6. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice. Nagatsu T Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515 [No Abstract] [Full Text] [Related]
7. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Heikkila RE; Sieber BA; Manzino L; Sonsalla PK Mol Chem Neuropathol; 1989 Jun; 10(3):171-83. PubMed ID: 2669769 [No Abstract] [Full Text] [Related]
8. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys. Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225 [TBL] [Abstract][Full Text] [Related]
9. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503 [TBL] [Abstract][Full Text] [Related]
10. Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism. Chiueh CC Ann N Y Acad Sci; 1988; 515():226-38. PubMed ID: 3259118 [No Abstract] [Full Text] [Related]
11. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Rojo AI; Cavada C; de Sagarra MR; Cuadrado A Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941 [TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and animal studies of Parkinson's disease. Oertel WH; Kupsch A Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901 [TBL] [Abstract][Full Text] [Related]
13. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences]. Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005 [TBL] [Abstract][Full Text] [Related]
14. The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys. Parent A; Lavoie B; Smith Y; Bédard P Adv Neurol; 1990; 53():111-6. PubMed ID: 1978512 [TBL] [Abstract][Full Text] [Related]
15. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787 [TBL] [Abstract][Full Text] [Related]
16. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722 [TBL] [Abstract][Full Text] [Related]
17. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701 [TBL] [Abstract][Full Text] [Related]
18. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage. Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624 [TBL] [Abstract][Full Text] [Related]
19. The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys. Parent A; Lavoie B Adv Neurol; 1993; 60():25-33. PubMed ID: 7678366 [TBL] [Abstract][Full Text] [Related]